ENCE CHUCK (Chief Financial Officer) purchased 50.8% of their position (136K shares) of RELMADA THERAPEUTICS, INC. on the open market
Open‑market purchase worth $299.2K — a major conviction buy. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 11/6/2025ACC: 0001213900-25-106838
Officer· Chief Financial Officer
Since Jul 2019
+136K
Net shares
Net buyer
$299.2K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
136K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+136K
Price / share
$2.20
Trade value
$299.20K
% of position
50.8%
11/5/2025
267.93K→403.93K
Total
Net shares
+136K
Net value
$299.20K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 11/5/2025 | P · Purchase | +136K | $2.20 | $299.20K | 50.8% | 267.93K | 403.93K |
| Total | +136K | $299.20K | ||||||
Derivative Transactions0
No derivative transactions reported